Dr. Teri Greiling, MD, PHD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 340
Licensed in Washington since 2021, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Washington School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
WA license MD.MD.61209644 (first issued 2021; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
- Hillsboro Medical Center Hillsboro, OR
- Columbia Memorial Hospital Astoria, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 340
- Services billed
- 1,030
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 301 | 55 |
| Established patient office or other outpatient visit, 20-29 minutes | 215 | 149 |
| Established patient office or other outpatient visit, 30-39 minutes | 109 | 72 |
| Destruction of precancer skin growth, 1 growth | 96 | 66 |
| Biopsy of related skin growth, first growth | 58 | 46 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 28 | 28 |
| Biopsy of related skin growth, each additional growth | 24 | 15 |
| Destruction of skin growth, 1-14 growths | 20 | 15 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 20 | 19 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 20 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in Seattle, WA | 77 |
| Prednisone Other prescribers in Seattle, WA | 74 |
| Triamcinolone Acetonide Other prescribers in Seattle, WA | 60 |
| Ketoconazole Other prescribers in Seattle, WA | 51 |
| Methotrexate (methotrexate sodium) Other prescribers in Seattle, WA | 50 |
| Tacrolimus Other prescribers in Seattle, WA | 44 |
| Betamethasone Dipropionate Other prescribers in Seattle, WA | 43 |
| Minoxidil Other prescribers in Seattle, WA | 35 |
| Doxycycline Monohydrate Other prescribers in Seattle, WA | 34 |
| Dapsone | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $150 in total to this clinician.
| Janssen Biotech, Inc. | $150 |
|---|
| Food and Beverage | $150 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $64,600 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. · Completed · NCT04206553 - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Eli Lilly and Company · Completed · NCT03570749
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.